TNGXTango TherapeuticsTNGX info
$3.10info5.44%24h
Global rank14312
Market cap$316.17M
Change 7d2.99%
YTD Performance-68.37%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Tango Therapeutics (TNGX) Stock Overview

    Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

    TNGX Stock Information

    Symbol
    TNGX
    Address
    201 Brookline AvenueBoston, MA 02215United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.tangotx.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    857 320 4900

    Tango Therapeutics (TNGX) Price Chart

    -
    Value:-

    Tango Therapeutics Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $3.10
    N/A
    Market Cap
    $316.17M
    N/A
    Shares Outstanding
    101.99M
    N/A
    Employees
    110.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org